Maso Capital Partners’s Vicarious Surgical RBOT Stock Holding History

Maso Capital Partners’s Portfolio RBOT Stock Details RBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$2.99M	–	46
2021 Q2	$2.99M	Hold	10,000	–	–	0.98%	17
2021 Q1	$2.98M	Buy	+10,000	New	+$3.06M	1.15%	14

Other funds holding RBOT

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

Aspex Management (HK) Central, Hong Kong $6.9B AUM 28.37% 1-Year Est. Return

Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Maso Capital Partners's RBOT Position: Q3 2021 in Review

Maso Capital Partners sold out of Vicarious Surgical (RBOT) in Q3 2021, closing a stake of 10,000 shares — an estimated $2.99M sold.

Maso Capital Partners first reported a position in RBOT in Q1 2021 and held it in 2 quarters. The position peaked at $2.99M in Q2 2021. 35 funds tracked by Wall St. Rank hold RBOT as of Q3 2021.

Maso Capital Partners reported no remaining Vicarious Surgical position as of Q3 2021 after selling out during the quarter.
Maso Capital Partners sold 10,000 Vicarious Surgical shares in Q3 2021, an estimated $2.99M.
Maso Capital Partners first reported a position in Vicarious Surgical in Q1 2021 and held it in 2 quarters.
Maso Capital Partners's Vicarious Surgical position peaked at $2.99M in Q2 2021.
35 funds tracked by Wall St. Rank held Vicarious Surgical as of Q3 2021.

Based on Maso Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.